PCI debuts expansion of its Rockford, Illinois, facility

Pills and vitamins
PCI Pharma Services has opened the doors to a 30,000-square-foot expansion of its facility in Rockford, Illinois. (Steven Depolo/CC BY 2.0)

PCI Pharma Services, a pharma/biopharma outsourcing provider, has unveiled an expansion of its plant in Rockford, Illinois, featuring additional primary and secondary packaging as well as labelling of clinical supplies. 

The 30,000-square-foot expansion also includes a temperature-controlled suite.

Construction on the project began in November last year and was recently completed. The cost of the project wasn’t disclosed. The expansion also includes a new customer reception area and additional office space.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

“This investment is one of many PCI is making across our global clinical supply chain in strategic location in the U.S., U.K., Europe and Australia to ensure we can meet our clients’ global needs by packaging and delivering life-saving therapeutic products to patients worldwide,” Brad Payne, PCI’s chief operating officer, said in a statement.

Earlier this year, PCI announced it would boost its capacity for clinical services with the addition of a 75,000-square-foot facility near Dublin that can serve as both a primary and secondary packaging, storage, logistics and distribution center. 

At the time of that announcement, Salim Haffar, PCI’s chief executive, said the company’s strategy was to continue to expand its global network in support of growing customer demand as well as provide a solution for Brexit through ongoing investment in capacity, capability expansion and talent.

RELATED: PCI Pharma Services takes steps to prepare for Brexit

PCI, like CDMOs such as Almac and Wasdell Group, has been expanding its footprint—particularly in Ireland—to prepare for disruption in the pharmaceutical market that is likely to occur with Brexit. 

Suggested Articles

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.